general news

AusCann strikes distribution agreement in medicinal cannabis

AusCann strikes distribution agreement in medicinal cannabis
AusCann strikes distribution agreement in medicinal cannabis
In what seemed like an audacious step, AusCann has struck an exclusive storage and distribution agreement with Clifford Hallam Healthcare (CH2), a national pharmaceuticals provider. AusCann was quoted saying that the agreement to distribute and store its pharmaceutical products would extend the company's distribution footprint in the Australian shores and would prove to be cost-effective.

AusCann was reported saying that pharmacies for AusCann will receive the products supplied by CH2, which would adhere to the regulations overseeing the supply of an unregistered medicine.

The deal will be valid for 12 months with an option to extend further. Notably, the deal replaces the heads of agreement inked by AusCann with Australian Pharmaceutical Industries Limited in early 2018.

The company says that the agreement marks yet another step on their path towards making available the hard-shell capsules for prescription and clinical evaluation to patients through the therapeutic Goods Administration (TGA) special access scheme and authorized prescriber scheme during the first half of 2020 in Australia.

The company emphasizes production, development and cannabinoid-based medicines in the Australia shores and overseas. The company described itself as bringing a paradigm shift in the way medicinal cannabis was supplied by making dose-controlled, standardized, cannabinoid-based pharmaceutical products and clinical evidence accessible to physicians, patients and healthcare providers
The Perth-based company allows physicians to treat their patients with a stable, reliable and standardized cannabinoid-based pharmaceutical product, adjust treatment algorithms and monitor treatment results using a portfolio of formulations and products.

AusCann is set to receive cannabis resin following the three-year deal inked with Tasmanian Alkaloids in Q3 2019. With an option of a three-year extension, it would supply minimum 30% of cannabis resin of AusCann for three years.

About AusCann
The company partners with leading market players and industry exprts to build an operation boosting the medicinal cannabis value chain, thereby fueling the delivery of economical, high-quality and clinically validated cannabinoid medicines to the Australian patients.

Source credit:

About the author

Saloni Walimbe

With an MBA-Marketing qualification under her belt, Saloni has always had a penchant for words, and holds two years of considerable experience as a content writer in the advertising field. She is currently following her passion for content creation by penning down insightful articles for and a few other news websites.